Report contents
Industry landscape
Where the company competes: a concentrated drug class with prices set country by country
Novo Nordisk sells prescription medicines for diabetes, obesity and rare disease, and one molecule family carries the company. Diabetes care supplied about 67% of 2025 sales and obesity care about 27%, with rare disease at 6%, according to the company's 2025 annual report. Semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management, sits behind most of that; adding the reported GLP-1 diabetes line to obesity care puts incretin therapy at roughly three quarters of group sales, an estimate based on the reported product lines. The arena that matters is branded GLP-1 receptor agonist therapy (drugs that mimic a gut hormone to lower blood sugar and blunt appetite) for type 2 diabetes and chronic weight management.
Who holds the pricing pen
Novo occupies the branded-molecule link of the pharmaceutical chain: it funds discovery, runs the trials, owns the manufacturing and employs the sales force. Upstream, the binding constraint is peptide production and fill-finish capacity, the step where a drug is put into its injector pen. Novo's 2025 annual report attributes part of the gross margin decline to 81.0% from 84.7% to amortization of the three former Catalent fill-finish sites it took over in 2024, plus capacity expansion. Capacity carries a real cost and is not instantly replicable, which strengthens the position of anyone already past it.
Downstream, the customer with power is not the patient. In the US, pharmacy benefit managers and insurers decide formulary placement and negotiate rebates, which is why Novo's US sales move with gross-to-net adjustments, as the annual report notes. In Europe, Canada, Japan and China, government bodies set or negotiate price. Most of the economics sit with the branded drug, but the price is agreed market by market, not set by the seller.
That geography shapes the competition. Approval, reimbursement and price are national; research and manufacturing are global. Novo reports US Operations separately from International Operations, which splits into EUCAN (Europe and Canada), Emerging Markets, APAC and Region China. A strong US formulary position buys nothing in Germany, and Chinese volume growth does not carry the same margin per patient. Scale economies live in manufacturing and the trial program; revenue is decided one health system at a time.
Market structure: two scaled suppliers, expanding class
IQVIA data for the 12 months to November 2025, cited in the annual report, put Novo's position as follows.
| Arena | Novo measure | Novo share |
|---|---|---|
| Global branded GLP-1 obesity | share of branded volume | 59.6% |
| Global diabetes | share of value | 30.1% (down 3.6 percentage points year over year) |
| GLP-1 therapy for type 2 diabetes | share of value | 45.8% |
The obesity figure leaves about 40% for everyone else. The only rival branded incretin with a scaled obesity presence that Novo's report names is Eli Lilly's tirzepatide, so this is close to a two-supplier race at the top. Novo also flags a data quirk: in International Operations, IQVIA books tirzepatide under GLP-1 diabetes only, even where it is approved for obesity. If that understates rival obesity volume outside the US, Novo's 59.6% is flattered, which the disclosure does not settle.
The class is still expanding into the patient pool. GLP-1 drugs were an estimated 8.1% of total diabetes prescriptions, up from 6.7% a year earlier, so share gains have come partly from a growing market instead of only from each other. Insulin remains a three-supplier business of Novo, Lilly and Sanofi, and it is shrinking.
Barriers to entry look high. A new incretin needs a multi-year cardiovascular outcomes trial, approval from the FDA or the European Medicines Agency, certified peptide capacity, and physician habits built over years. The 3.6-point drop in diabetes value share shows what those barriers protect: the class, not any one member of it. An approved competitor joins the same small club and can take share without having to break into the market from outside. That makes this an oligopoly with real turnover inside it, and it makes the durability of Novo's obesity lead a question about relative product performance and payer contracts, not about whether outsiders can enter at all.
Competitive advantage
Does the company have a moat? Yes, though Novo is spending it on capacity
Novo Nordisk's barriers to entry are real, but the place to see them has moved from the income statement to the balance sheet. The company earned an estimated 57% to 72% after-tax return on invested capital (ROIC: operating profit after tax divided by the equity, debt and cash tied up in the business) in fiscal 2021 through 2024. In fiscal 2025 it earned about 34% on a similar operating profit, because invested capital rose from DKK 83.4 billion to DKK 298.6 billion while NOPAT (operating profit after tax) went from DKK 47.5 billion to DKK 101.0 billion. Novo traded part of its return for capacity. The moat now has to be re-earned on a base nearly four times larger, just as revenue growth slowed to 6.4% in 2025 from 25.0% in 2024.
That is what a barrier looks like in a two-supplier drug class. Approval requires a multi-year cardiovascular outcomes trial, and selling at scale requires peptide manufacturing and fill-finish lines that take years to certify, so the list of credible competitors stays short and returns stay wide. Novo's gross margin has not dropped below 77% in any period covered here and its net margin has not dropped below 21%, spreads that would ordinarily pull capital into the market and close the gap.
Market position: first or second in every arena that matters
Market position: Strong. IQVIA data for the 12 months to November 2025, cited in Novo's 2025 annual report, put the company at 59.6% of global branded GLP-1 obesity volume and 45.8% of GLP-1 diabetes value. In the broader diabetes market, which includes insulin, Novo holds 30.1% of value, which places it first or second alongside Eli Lilly and Sanofi. The obesity arena carries the growth, and there Novo's lead is measured against a single competing molecule rather than a crowd.
Stability of position: Moderate. Novo's 30.1% share of global diabetes value fell 3.6 percentage points in the year to November 2025, according to the same IQVIA figures. A five-year average share swing of more than five percentage points usually signals that no barrier exists, and one of less than two points suggests a strong one; a single documented year of 3.6 points sits between those tests and cannot settle it. Fewer than three years of comparable share data are public, so five-year stability is not established either way. What the record does show is that the erosion is concentrated in diabetes value while the obesity franchise held its share.
Returns: exceptional, and diluted by Novo's own building program
The financial statements cover fiscal 2021 through 2025 and three quarters of 2026. The ROIC figures below are estimated: NOPAT is operating income times one minus the tax rate, the tax rate is the tax provision divided by EBIT, and invested capital is total equity plus short- and long-term debt minus cash.
| Fiscal year | NOPAT (DKK bn) | Invested capital (DKK bn) | ROIC (%) |
|---|---|---|---|
| 2021 | 47.5 | 83.4 | 57 |
| 2022 | 60.2 | 93.1 | 65 |
| 2023 | 82.1 | 114.6 | 72 |
| 2024 | 102.2 | 225.2 | 45 |
| 2025 | 101.0 | 298.6 | 34 |
Core returns: Strong. Even the trough year, 34% in 2025, sits well above the 15%-25% average that a decade of returns usually needs to clear before an advantage is credited. Return on equity ran higher still, 88.1% in 2023 and 60.7% in 2025, but leverage flatters it: total liabilities rose to 24.1% of assets at the end of 2025 from 7.1% at the end of 2023 as debt funded the build-out. ROIC is the cleaner measure of the operating business, and it is the one that halved.
Margins: Strong. Gross margin went from 84.7% in fiscal 2024 to 81.0% in fiscal 2025 and 77.0% in the third quarter of 2026. Net margin moved from 34.8% to 33.1% and then to 21.1% in that third quarter. Scale is doing real work: revenue of DKK 309.1 billion and net income of DKK 102.4 billion in 2025 spread DKK 52 billion of research spending, roughly 17% of sales, across a base few rivals can match.
The third quarter of 2026 carries a warning. Revenue rose 5.6% from a year earlier while operating income fell 2.8%, and the net margin dropped 5.6 percentage points. Novo's September 2026 capital markets day presentation defines its adjusted sales to exclude 340B provision reversals (a US drug discount program for hospitals and clinics) and its adjusted costs to exclude major legal matters and impairments, which means reported quarters can contain items of that size. The first quarter of 2026, at a 50.2% net margin, is far out of line with the 26.7% and 21.1% of the two following quarters, and reported line items do not identify what drove the gap.
Overall rating: Fairly Strong
The two dimensions that decide whether a moat exists both score well: a top-two position in a market with few credible sellers, and returns that have not fallen below 34% even in the heaviest investment year. That combination is not what a contested market produces. What keeps the rating at Fairly Strong rather than Strong is the direction of travel in 2026. Growth has slowed to between 2% and 6% a quarter, operating income is falling in the last two reported quarters, diabetes value share slipped, and gross margin is down 7.7 percentage points from fiscal 2024 to the third quarter of 2026. A barrier that protected returns fully would not show all four at once.
Where the advantage comes from: peptide capacity, and a payer that can say no
Three bodies of evidence carry this section. Novo's annual report and 20-F give the capital, margin and spending record; IQVIA share data reproduced in the annual report measure the branded market Novo actually sells into; and the September 2026 capital markets day presentation shows where the money has gone. The single number that tests the moat most directly is Novo's share of branded GLP-1 obesity volume, 59.6% in the 12 months to November 2025. Hold near that level against a rival molecule and the advantage is intact; watch it fall through the 50s and the manufacturing lead is no longer converting into customers.
Manufacturing: Strong, and the clearest barrier Novo owns
Peptide production and fill-finish, the step where a drug is loaded into an injector pen, are the binding constraint on this class, and Novo has spent heavily to own them. Net property, plant and equipment rose from DKK 55.4 billion at the end of 2021 to DKK 208.4 billion at the end of 2025, with investing cash outflows of DKK 128.9 billion in fiscal 2024 and DKK 79.2 billion in fiscal 2025. That spending took free cash flow down to DKK 29.0 billion in 2025 from DKK 69.7 billion in 2024. The payoff is visible in the margin: on 2025 revenue of DKK 309.1 billion, an 81.0% gross margin leaves roughly DKK 250 billion before research and selling costs, an estimate from reported figures, against DKK 52 billion of research spending. A challenger has to fund a comparable trial program and secure certified peptide capacity before it earns a single krone.
Why patients stay is partly reliability. A chronic weekly injection is a poor place to risk a shortage, so pharmacies, distributors and payers contract with suppliers who can deliver volume on schedule, and Novo's capacity is the reason it can. Why rivals cannot simply buy their way in is that the 2024 purchase of three fill-finish sites from Catalent took a contract manufacturer out of the merchant market, which may have left would-be entrants with fewer places to buy capacity; Novo does not quantify that effect. What would break the advantage: capacity stops being scarce. If a rival adds comparable fill-finish lines, or if an oral incretin with adequate efficacy moves most patients from pens to tablets, where contract manufacturing is abundant, the bottleneck that protects Novo disappears along with it. Patent expiry on semaglutide would do the same more abruptly, turning a scarce molecule into a commodity.
Customer captivity: Moderate, because the payer holds the prescription pad
The patient is not the customer who decides. In the US, pharmacy benefit managers and insurers choose formulary placement each year and negotiate rebates, and Novo's own segment reporting separates US operations from international ones because the economics differ by health system. In Europe, Canada, Japan and China, government bodies set or negotiate price. That structure limits captivity in a way brand advertising cannot fix: a rival's discount can move a large block of patients within one contract cycle. The evidence for that is the 3.6-point decline in diabetes value share over a single year, against a molecule that had no difficulty being adopted.
Prescriber habit is the real asset here, built over decades of selling insulin and GLP-1 drugs to the same physicians, and it shows up in a 30.1% share of global diabetes value. Habit, though, is not the same as lock-in. A different molecule in the same class works through the same biology, carries no retraining cost for the physician, and requires no change for the patient beyond a new pen. Recognition of the Ozempic and Wegovy names does not create switching costs when the insurer is paying and the doctor is choosing on efficacy and coverage. What would break this: a formulary exclusion at a large US payer, which would show up as a step down in obesity volume share within two quarters.
Scale in research and sales: Fairly Strong, but it magnifies whoever has the better molecule
Research spending of DKK 52 billion in 2025, almost triple the DKK 18 billion of 2021, is a fixed cost spread across a revenue base that few competitors can match. The same is true of the outcomes trials regulators require and the sales coverage needed to call on specialists in every major market. Minimum efficient scale here, the volume at which a newcomer's per-unit costs fall to the incumbent's, is high enough that a new entrant must win large volume before it earns a normal return, and approval requirements raise that fixed cost further.
Scale is not captivity, however. Eli Lilly already has comparable scale and a competing molecule, so Novo's size does not stop a better product from taking formulary position. Scale amplifies whichever company has the more effective drug and the more reliable supply; it does not determine which one that is. What would break this advantage: a competitor demonstrating clearly better weight loss or cardiovascular outcomes, at which point Novo's fixed-cost base becomes a cost to defend rather than a barrier to entry.
Durability: the substitute that matters is a cheaper route to the same hormone
Novo's risk is not that patients abandon weight loss. It is that they reach the same biology through a cheaper product, whether an oral incretin, a competitor's injectable, or a older generic that payers prefer for cost reasons. A large share of the eligible population is still untreated, so volume can grow for years even as price per patient falls; that combination would lift revenue while compressing the margin that makes the returns exceptional.
The evidence at hand shows the margin already moving in that direction, from 84.7% to 77.0% over seven quarters. Novo's defense rests on holding roughly 60% of obesity volume while its manufacturing base keeps supply reliable and its research budget keeps the pipeline ahead of rivals. The moat looks durable for the next several years and considerably less certain beyond the point when injectable capacity stops being scarce or semaglutide's patents run out.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Comparison and summaryHow Novo Nordisk A/S compares with its closest rivals, and our moat rating
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on Novo Nordisk A/S
Novo Nordisk A/S
Business, moat and key questions
Open company page